Whole Genome Sequencing

Complete whole genome sequencing with expert genetic analysis and clinical interpretation. Maps the full three billion base pairs of the patient's DNA, identifying genetic variants relevant to disease risk, pharmacogenomics, carrier status, and wellness-related traits.

Whole genome sequencing (WGS) reads the entirety of an individual's genetic code — approximately three billion base pairs of DNA — providing the most comprehensive genetic dataset currently obtainable. Unlike targeted genetic panels that examine a limited number of genes associated with specific conditions, WGS captures the full picture, including coding regions (exons), regulatory regions, and structural variants that panels typically miss. The clinical interpretation at Welbeck focuses on actionable findings: genetic variants associated with elevated risk for conditions where early intervention, enhanced screening, or lifestyle modification can meaningfully alter outcomes. This includes hereditary cancer syndromes (such as BRCA1 and BRCA2 for breast and ovarian cancer risk), cardiovascular genetic conditions (familial hypercholesterolaemia, cardiomyopathies), and pharmacogenomic variants that affect how an individual metabolises common medications. Carrier status for recessive conditions relevant to family planning is also reported. The value of WGS lies in its permanence and forward compatibility — the data is sequenced once but can be reanalysed as genetic science advances and new variant-disease associations are discovered. As a standalone service, it is suited for individuals who want a foundational genetic map. When combined with a Welbeck Executive Screen, the genomic data enriches the interpretation of imaging and blood work findings, creating a truly personalised risk profile. The add-on price with an executive screen is significantly reduced compared with the standalone cost.